383 completed, 295 recruiting, 214 terminated, 159 unknown. 675 Phase 1, 671 Phase 2, 106 Phase 3, 46 Not applicable, 44 Early Phase 1.
Follow fludarabine: new trials by email Literature Review of fludarabine trials Research Report on fludarabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study of GC012F in Rheumatoid Arthritis. LD and GC012F CAR-T Cell Injection, GC012F CAR-T Cell Injection - Rheumatoid Arthritis | Early Phase 1 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2027-12-01 | 2026-06-10 | |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome Busulfan, Melphalan, Fludarabine - Myelodysplastic Syndromes, Graft Vs Host Disease | Not applicable | Not yet recruiting | Guenther Koehne | 62 | 2027-01-01 | 2026-10-13 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| TCR1188-ABC Cells in KRAS-mutated Cancers TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of Pennsylvania | 30 | 2026-12-01 | 2026-10-14 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-10-13 |
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors Chimeric receptor T-cells + Trastuzumab, Fludarabine and Cyclophosphosphamide - HER2+ Advanced Breast Cancer, Other Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | National University Hospital, Singapore | 36 | 2026-11-01 | 2025-09-23 |
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-11-01 | 2026-07-30 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
Showing 20 of 1314. Sign in to see all of them.
Leukemia, Myeloid, Acute (252) · Myelodysplastic Syndromes (160) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (149) · Leukemia, Lymphocytic, Chronic, B-Cell (141) · Leukemia (129) · Multiple Myeloma (122) · Lymphoma (117) · Lymphoma, Non-Hodgkin (113) · Recurrence (96) · Hematologic Neoplasms (77) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (69) · Hodgkin Disease (68) · Melanoma (68) · Lymphoma, B-Cell (62) · Lymphoma, Mantle-Cell (52)
M.D. Anderson Cancer Center (117) · National Cancer Institute (NCI) (82) · Masonic Cancer Center, University of Minnesota (42) · Fred Hutchinson Cancer Center (33) · Kite, A Gilead Company (32) · St. Jude Children's Research Hospital (31) · Baylor College of Medicine (27) · City of Hope Medical Center (22) · Memorial Sloan Kettering Cancer Center (22) · Beijing Biotech (21) · H. Lee Moffitt Cancer Center and Research Institute (17) · Chinese PLA General Hospital (15) · Fate Therapeutics (13) · Hoffmann-La Roche (13) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (13)
United States (853) · China (227) · Germany (78) · France (70) · Canada (60) · Spain (60) · Italy (52) · Australia (50) · United Kingdom (49) · Netherlands (38) · South Korea (35) · Belgium (29) · Sweden (26) · Austria (25) · Denmark (25)
Steven A Rosenberg, M.D. (25) · James N Kochenderfer, M.D. (8) · Brandon Triplett, MD (7) · Richard E. Champlin, MD (7) · Weidong Han, Ph.D (7) · Christopher G Kanakry, M.D. (6) · James C Yang, M.D. (6) · Mary Horowitz, MD (6) · Michael Hallek, MD (6)
PMID 34515338, PMID 33242441, PMID 23861247, PMID 25310303, PMID 30714987, PMID 32747469, PMID 36240296, PMID 15812540, PMID 18997171, PMID 19144982, PMID 20685256, PMID 21195303, PMID 21403127, PMID 22055111, PMID 22430088, PMID 22442346, PMID 22493293, PMID 22555974, PMID 24812403, PMID 25753432, PMID 26429297, PMID 26869630, PMID 27507877, PMID 27561722, PMID 27959684, PMID 28380315, PMID 28751559, PMID 31208944, PMID 31401903, PMID 32343796, PMID 34385708, PMID 34893603, PMID 34935483, PMID 35537408, PMID 37192741, PMID 38620092, PMID 38635762, PMID 38816232, PMID 39240498, PMID 39946666, PMID 42477805, PMID 42668697, PMID 10586336, PMID 11015443, PMID 11034090, PMID 11313690, PMID 12242449, PMID 12651206, PMID 12721664, PMID 14550808
P30CA033572 (16), 2023 (15), 2019 (10), 2015 (9), U24CA076518 (8), 2018 (6), 2025 (6), P30CA015704 (6), U01HL069294 (6), 2005 (5), 2017 (5), 2008 (4), P30CA016672 (4), P01CA015396 (3), P01CA018029 (3)